Article | April 15, 2021

Viral Vector Scale-Up: How Can We Bridge The Technology Gaps?

Source: Cytiva

By Joe Makowiecki, Enterprise Solutions Director of Business Development, and Harlan Knapp, Business Development Manager, Cytiva

iStock-1197475842-bridge-gap

Viral vectors have been playing an important role in the growing cell and gene therapy market. Seven of the FDA-approved cell and gene therapies utilize or are viral vectors. Now, nearly a quarter of COVID-19 vaccines in development require viral vectors for the spike protein delivery. The FDA predicts that, by 2025, the agency will approve 10 to 20 cell and gene therapy products each year.

However, complex and challenging manufacturing processes may affect the ability to efficiently produce viral vectors on a larger scale. To unlock their full potential, we must understand the existing difficulties in viral vector production and which upstream and downstream processing technologies are now available.

This article reviews your options for viral vector manufacturing, the upstream challenges and downstream considerations in viral vector production, and integrating automation in and selecting a vendor for your viral vector manufacturing line.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online